Literature DB >> 15361770

Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity.

Masato Furuhashi1, Nobuyuki Ura, Hideki Takizawa, Daisuke Yoshida, Norihito Moniwa, Hideyuki Murakami, Katsuhiro Higashiura, Kazuaki Shimamoto.   

Abstract

OBJECTIVE: Based on results of in vitro studies, it has been hypothesized that blockade of the renin-angiotensin system (RAS) promotes the recruitment and differentiation of pre-adipocytes and that increased formation of small insulin-sensitive adipocytes counteracts ectopic deposition of lipids, thereby improving insulin sensitivity. We investigated the effect of RAS blockade on insulin sensitivity, adipocyte size, and intramuscular lipid content in fructose-fed rats (FFR) as a model of insulin-resistant hypertension. DESIGN AND METHODS: Six-week-old male Sprague-Dawley rats were divided into two groups: those fed a standard chow (control) and those fed a fructose-rich chow for 6 weeks. FFR were treated with a vehicle or with 1 mg/kg per day of temocapril, an angiotensin-converting enzyme inhibitor, or 0.1 mg/kg per day of olmesartan, an angiotensin II type 1 receptor blocker, for the last 2 weeks. Insulin sensitivity (M value: mg/kg per min) was estimated by the euglycemic hyperinsulinemic glucose clamp method. Sizes of adipocytes derived from epididymal fat and triglyceride content in the soleus muscle were determined.
RESULTS: FFR had lower M value, higher blood pressure, larger adipocyte size, higher ratio of epididymal fat pads over body weight (%fat pads), and higher intramuscular triglyceride than did the control rats. Both temocapril and olmesartan significantly improved the M value and decreased blood pressure and adipocyte size without change in %fat pads in FFR. Adipocyte size was negatively correlated with the M value. Treatment for 2 weeks decreased, but not significantly, intramuscular triglyceride.
CONCLUSIONS: RAS blockade decreases adipocyte size without change in epididymal %fat pads accompanied by improvement in insulin sensitivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15361770     DOI: 10.1097/00004872-200410000-00021

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  38 in total

1.  Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Linda Fried; Ping Tepper; Emma Barinas-Mitchell; Molly B Conroy; Rhobert W Evans; Maria Mori Brooks; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Hypertens Res       Date:  2013-05-09       Impact factor: 3.872

2.  Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.

Authors:  Mark A Munger
Journal:  P T       Date:  2011-01

Review 3.  The renin angiotensin system and the metabolic syndrome.

Authors:  Annette D de Kloet; Eric G Krause; Stephen C Woods
Journal:  Physiol Behav       Date:  2010-04-08

4.  Timing of fructose intake: an important regulator of adiposity.

Authors:  Mariana Morris; Iara C Araujo; Roberta L Pohlman; Mariana C Marques; Naima S Rodwan; Vera M A Farah
Journal:  Clin Exp Pharmacol Physiol       Date:  2012-01       Impact factor: 2.557

Review 5.  The intricacies of the renin-angiotensin-system in metabolic regulation.

Authors:  Erin B Bruce; Annette D de Kloet
Journal:  Physiol Behav       Date:  2016-11-22

Review 6.  ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme.

Authors:  David Aguilar; Scott D Solomon
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Prolonged ingestion of ovalbumin diet by sensitized mice improves the metabolic consequences induced by experimental food allergy.

Authors:  N V Batista; R V S Pereira; M L M Noviello; L P A Dourado; D A Perez; G Foureaux; A J Ferreira; A V M Ferreira; D C Cara
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 8.  Chronic inflammation in obesity and the metabolic syndrome.

Authors:  Rosário Monteiro; Isabel Azevedo
Journal:  Mediators Inflamm       Date:  2010-07-14       Impact factor: 4.711

9.  Angiotensin type 1a receptors in the paraventricular nucleus of the hypothalamus protect against diet-induced obesity.

Authors:  Annette D de Kloet; Dipanwita Pati; Lei Wang; Helmut Hiller; Colin Sumners; Charles J Frazier; Randy J Seeley; James P Herman; Stephen C Woods; Eric G Krause
Journal:  J Neurosci       Date:  2013-03-13       Impact factor: 6.167

10.  Combination of captopril and allopurinol retards fructose-induced metabolic syndrome.

Authors:  Carlos A Roncal; Sirirat Reungjui; Laura Gabriela Sánchez-Lozada; Wei Mu; Yuri Y Sautin; Takahiko Nakagawa; Richard J Johnson
Journal:  Am J Nephrol       Date:  2009-08-21       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.